Kornimate/medical-research-clean huggingface dataset:
radiofrequency microtenotomy for treatment of rotator cuff tendinopathy

Conditions: Shoulder Impingement Syndrome

Summary: this study compare the outcome (pain, function) after radiofrequency microtenotomy (group i) and acromioplasty (group ii) for treatment of rotator cuff tendinosis in the shoulder. the outcome of both methods will be compared to the physical therapy treatment (groupiii)

rotator cuff tendinosis cause pain and disability of the shoulder. tendinosis, sometimes complicated by partial rupture, appears to be the major lesion in chronic rotator cuff tendinopathy. important features is a poor intrinsic ability to heal. several patients receive treatment for shoulder tendinosis each year. conservative treatments options include rest, stretching, strengthening, ice and/or physical therapy are used with difference results. a traditional surgical treatments (acromioplasty) have been reported with variable results.. the aim of this study is to evaluate improvement of vas and functionality using constant score before and after treatment of rotator cuff tendinosis using radiofrequency-plasma based microtenotomy in comparison to traditional acromioplasty and physical therapy.

Eligibility criteria:
inclusion criteria: * impingement pain in the shoulder at least 3 months * mri of shoulder reveal tendinosis * classification of acromion morphology by rtg and or mri * daily pain exclusion criteria: * inflammatory joint disease * other comorbidity in the shoulder as instability, osteoarthritis or rotator cuff tear * serious illness

Keywords: rotator cuff tendinosis impingement radiofrequency
chronic pain master protocol (cpmp): a study of ly3526318 in participants with chronic low back pain

Conditions: Chronic Low-back Pain

Summary: the purpose of this study is to test whether ly3526318 is efficacious and safe in relieving chronic low back pain (clbp). this trial is part of the chronic pain master protocol h0p-mc-cpmp (nct05986292) which is a protocol to accelerate the development of new treatments for chronic pain.


Eligibility criteria:
inclusion criteria: * have a visual analog scale (vas) pain value ≥40 and \<95 during screening. * have a history of daily pain for at least 12 weeks based on participant report or medical history. * have a body mass index \<40 kilograms per meter squared (kg/m²) (inclusive). * are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation. * are willing to discontinue all medications taken for chronic pain conditions for the duration of the study. * are at 18 years old or older at the time consent is signed. * have a history of low back pain for at least 3 months located between the 12th thoracic vertebra and the lower gluteal folds, with or without radiation. * have a history of low back pain as classified by the quebec task force category 1 through 3. * are men, or women able to abide by reproductive and contraceptive requirements. exclusion criteria: * have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques). * have surgery planned during the study for any reason, related or not to the disease state under evaluation. * have, in the judgment of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation. * have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision. * have fibromyalgia * have a substance use disorder as defined by the diagnostic and statistical manual of mental disorders (5th edition; dsm-5; american psychiatric association). * have a positive human immunodeficiency virus (hiv) test result at screening. * are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide. * have an intolerance to acetaminophen or paracetamol or any of its excipients. * have a history of alcohol, illicit drug, analgesic or narcotic use disorder within 2 years prior to screening. * have used a therapeutic injection (botulinum toxin or corticosteroids) in the 3 months prior to starting the washout period. * have history of or current compression fracture. * have had a recent major trauma (within 6 months of baseline). * have a history of low back pain as classified by the quebec task force categories 4 through 11. * are using a spinal cord stimulator or dorsal root ganglion stimulator. * are pregnant or breastfeeding.
g6pd deficiency in infarction patients in shaanxi province

Conditions: Cerebral Infarction; G6PD Deficiency

Summary: cerebral infarction brings heavy burden to patients and families with high morbidity, mortality, disability and recurrence rate. anti-platelet aggregation therapy plays important role for secondary prevention of cerebral infarction. g6pd deficiency is a rare genetic disorder, patients with this disorder could suffer hemolysis after eating broad beans. professor zeng jinsheng et al found that the hemolysis risk of g6pd deficiency patients was significantly increased when aspirin was applied in guangdong province. however, the prevalence of g6pd deficiency in northern china remains unknown, as well as the safety of antiplatelet therapy. to this end, 1000 patients with acute cerebral infarction will be continuously included in 30 second-level and above hospitals in 10 prefectures and cities of shaanxi province for observation and follow-up for 12 months, to explore the prevalence of g6pd deficiency in cerebral infarction patients in shaanxi province, and to analyze the relationship between g6pd deficiency and the clinical characteristics and prognosis of cerebral infarction. to clarify the efficacy and safety of antiplatelet therapy for g6pd patients with cerebral infarction is of great significance for guiding the individualized treatment of cerebral infarction.


Eligibility criteria:
inclusion criteria: * meets the diagnostic criteria of acute cerebral infarction established by neurology society of chinese medical association, and confirmed by cranial magnetic resonance imaging； * time from onset to enrollment ≤14 days; * volunteer to participate in the study and sign the informed consent. exclusion criteria: * silent cerebral infarction with no symptoms and signs; * complicated with post-infarction hemorrhage; * cerebral hernia and other complications caused by massive cerebral infarction may lead to death in acute phase; * cardiogenic cerebral embolism caused by atrial fibrillation; * cerebral infarction caused by tumor, vasculitis and other special reasons; * complicated with serious systemic diseases, including liver and kidney insufficiency, respiratory failure, heart failure, infection, etc

Keywords: cerebral infarction g6pd deficiency hemorrhagic transformation antiplatelet therapy antioxidant therapy
a study to evaluate a possible superiority expressed by the faster onset of action and the efficacy and safety of sildenafil citrate 20mg sublingual tablet in the treatment of erectile dysfunction of different etiologies

Conditions: Erectile Dysfunction

Summary: the purpose of this study is to evaluate the tolerability and safety of sildenafil citrate 20mg sublingual tablet, as well as a possible superiority expressed by the faster onset of action compared to viagra ® 50mg tablet coated in erectile dysfunction.

phase iii clinical trial, comparative, open, multicenter, prospectively, with random inflow of 78 patients evaluable male patients with erectile dysfunction with iief-5 score in between 13 and 24, corresponding to mild or mild to moderate to evaluate the efficacy and safety as well as a possible superiority expressed by the faster onset of action onset of action of study medication.

Eligibility criteria:
inclusion criteria: * patients over 18 years; * patients with erectile dysfunction of various etiologies (organic, psychogenic and mixed) for at least 6 months; * patients with scores in the iief-5 between 13 and 24, which correspond to mild or mild to moderate; * relationship stable for at least 6 months; * patients should be kept with libido; * education at least 4 years; * do not use sildenafil, vardenafil, tadalafil, lodenafil, injection therapy or vacuum devices up to 72 hours before the screening visit; * functions hepatic, hematological, hormonal and renal within the following benchmarks: * creatinine: 0.6 to 1.10 mg / dl; * urea: 10 - 50mg/dl; * tgp: up to 40 u / l; * tgo: ≤ 34 u / l; * prolactin: 2.3 to 11.5 ng / ml men * total testosterone: 241 to 827 ng/100 ml - men * blood glucose: 70 mg / dl and 99mg/dl. exclusion criteria: * patients who have failed treatment with inhibitors of phospho-diesterase inhibitors; * patients undergoing radical prostatectomy; * patients with hypersensitivity to any component of the formula; * presence of genital deformities or other disorders that prevent intercourse; * operations prior to penile erectile dysfunction or premature ejaculation penis enlargement; * use of other treatments for erectile dysfunction or concomitant treatment with nitrates; * myocardial infarction or cerebrovascular accident (cva) for less than 6 months; * heart disease or uncontrolled serious; * injury cord injury; * multiple sclerosis; * retinitis pigmentosa; * neoplasms known in business and / or treatment; * history of severe anaphylactic reactions and disease steven-johnson; * participation in a clinical study in the 2 months prior to inclusion; * patients who are making use of antiretrovirals; * any other disease or condition is not matched that in the opinion of the investigator, could lead to increased risk for the patient or who makes it inappropriate for this study; * comorbidities such as diabetes mellitus, malignant hypertension, blood pressure (bp), systolic\> 170 mmhg, diastolic bp levels\> 110 mmhg, blood pressure \<80 x 50 mmhg, significant cardiovascular disease, alcohol or drugs, or other disorders important.

Keywords: phase iii sildenafil citrate tablet sublingual erectile dysfunction
a study to assess bioavailability and pharmacokinetics of cat- 354

Conditions: Asthma; Healthy

Summary: to compare bioavailability and pharmacokinetics of cat-354 following subcutaneous administration compared with intravenous administration.

to compare the bioavailability and pharmacokinetics of cat-354 following subcutaneous administration of 150 milligram (mg) and 300 mg compared with 150 mg given intravenously.

Eligibility criteria:
inclusion criteria: * signed and dated written informed consent is obtained prior to any study related procedure taking place * males, aged 19-55 years * no significant abnormality on clinical examination or medical history (excluding atopic skin signs, symptoms and history) * a normal 12-lead electrocardiogram (ecg) (no clinically significant abnormalities) * clinical chemistry, hematology and urinalysis results within the laboratory reference ranges or deemed not clinically significant by the investigator * a negative screen for drugs of abuse and alcohol * body mass index (bmi) between 18-30 kilogram per square meter (kg/m\^2), inclusive * no other clinically significant abnormality on history and clinical examination * able to comply with the requirements of the protocol. exclusion criteria: * any active concomitant disease including psychological disorders * history of medication that might carry over effects into study * previously received monoclonal antibody, or a similar related protein, that might sensitize subjects to cat-354 * participation in another investigational medicinal product study within 3 months of the start of this study or 5 half-lives of the previously administered investigational medicinal product (imp), whichever is the longer except methodological studies in which no imp was given * any acute illness in the 2 weeks before day 0 (visit 2) * any blood donation or significant loss of blood within 56 days of study initiation or plasma donation within 7 days of study initiation * subject is a participating investigator, sub-investigator, study coordinator, or employee of a participating investigator, or is a first degree relative of the aforementioned * any factor which, in the opinion of the investigator, would jeopardize the evaluation or safety or be associated with poor adherence to the protocol * the subject's primary care physician recommends the subject should not take part in the study * subjects with immunodeficiency disorders * subjects who have a positive test for, or have been treated for hepatitis b, hepatitis c or human immunodeficiency virus (hiv).

Keywords: asthma cat-354 tralokinumab healthy
national longitudinal cohort of hematological diseases (niche) - cart

Conditions: Hematological Malignancies

Summary: this is a multicenter, ambispective, longitudinal, observational cohort study investigating car-t cell therapy in chinese patients with hematological malignancies. a consortium of phase iv clinical trials and real-world studies of chimeric antigen receptors (car) t cell therapy will be established in china. patient-level data from these studies will be collected to create a large real-world cohort. in addition, patients receiving car-t cell therapy for hematological malignancies identified from an existing hematology longitudinal cohort study, the national longitudinal cohort of hematological diseases (niche), will also be included in the study.


Eligibility criteria:
inclusion criteria: * patients with clinically diagnosed hematologic malignancies * patients treated with car-t cell therapy * signed the informed consent form

Keywords: chimeric antigen receptors (car) t cell hematological malignancies
enhanced support for behavioral barriers to learning: an evaluation of the school stars program

Conditions: Disruptive Behavior Disorder, Childhood Onset; Attention Deficit Hyperactivity Disorder; Oppositional Defiant Disorder in Children; Disruptive Mood Dysregulation Disorder

Summary: this small pilot study will enroll children ages 5-12 years of age with disruptive behavior problems at school. these children and their families will be offered an enhanced model of primary care, which includes pre-visit record review, standardized content of primary care visits, post-visit care coordination by the primary care team, and coordination of services between the primary care team and the school. we hypothesize that children receiving this enhanced model of care will achieve better behavioral outcomes at both school and home.


Eligibility criteria:
inclusion criteria: * student at a local public school * primary care patient at the pediatric primary care center (ppc) at cchmc, or a cchmc-affiliated school-based health center * school disciplinary problems defined as: (1) any suspension from school within the last 2 school months and/or (2) frequent calls to the parent from school (1+ times per week x 1 month) * parent is in the contemplative, preparation, or action stage of readiness for starting medication or therapy if recommended by a healthcare provider for their child's behavior problems * student may or may not have an existing diagnosis of an externalizing behavioral health disorder, such as adhd, oppositional defiant disorder, or disruptive mood dysregulation disorder. exclusion criteria: * non-english-speaking parent * enrolled in another adhd study * severe developmental delay or autism * potential cardiac contraindications to starting stimulant medications without an ekg (personal or family history of heart disease in a child, family history of sudden death before age 50, family history of death due to heart disease before age 50, personal history of seizures, personal history of unexplained syncopal episodes) * patients who have an established relationship with a ppc care manager * patients who have seen the same primary care provider for the last two well child or behavior-related visits (unless approved/referred by that primary care provider)
pneumatic compression and post-induction hypotension

Conditions: Prostate Cancer

Summary: the purpose of this study is to evaluate the effect of pneumatic compression on post-induction hypotension in elderly patients undergoing robot assisted laparoscopic prostatectomy.

the purpose of this study is to evaluate the effect of pneumatic compression of lower leg, which is performed during 20 minutes after anesthesia induction period, on post-induction hypotension in elderly patients undergoing robot assisted laparoscopic prostatectomy.

Eligibility criteria:
inclusion criteria: * patients who are scheduled robot assisted laparoscopic prostatectomy under general anesthesia * elderly patients (between 65 and 79 years old) * american society of anesthesiologists physical status ≤3 * patients who are voluntarily agreed to this clinical study exclusion criteria: * uncontrolled hypertension, heart failure (ejection fraction \<40%), arrhythmia requiring treatment, unstable coronary artery disease * patient's denial
effects of a multimodal physical exercise and functional rehabilitation program on fatigue, pain, functional capacity and quality of life in cancer patients with tumor asthenia.

Conditions: Cancer; Cancer-Related Syndrome; Fatigue

Summary: tumor asthenia is the most common symptom associated with cancer and its treatment. although the estimated prevalence varies between 60-90%, and it is considered the longest-lasting symptom in cancer patients, having the greatest impact on quality of life parameters, it is a problem that is still undervalued in general by health professionals . it has been observed that individuals with this process find it difficult to normalize their daily life, either due to a deterioration in their clinical condition or due to a problem in the generalization of what they have learned during their hospital stay. that is why we plan to carry out a clinical trial, to evaluate the effect of a controlled patient follow-up program, and thus be able to address these difficulties in the most optimal way. a randomized clinical trial of two parallel groups will be carried out, belonging to the oncology service of the university hospital of salamanca. 44 participants with tumor asthenia, who are admitted at the time of inclusion, will be selected through a consecutive sampling. after the baseline evaluation, the participants will be randomized into two groups. the subjects of the experimental group will carry out a functional rehabilitation program, with a duration of one month. the main variable will be the evaluation of the basic activities of daily life (barthel scale). the secondary variables will be oriented to evaluate the change in tumor asthenia, attention and cognitive functions, parameters of quality of life, pain, functional capacity and body composition. the results of this study could be transferred to the clinic, incorporating them into care protocols for cancer patients with tumor asthenia.


Eligibility criteria:
inclusion criteria: * having among the reasons for admission a pathological diagnosis of newly diagnosed or relapsed oncological disease. * being admitted to the oncology service of the salamanca university hospital. * barthel index score between 15 and 55 points. * level of tumor asthenia greater than or equal to 4 on the eva scale for tumor asthenia. * sign an informed consent in which they authorize their voluntary participation in the study (annex ii). exclusion criteria: * present cognitive impairment assessed with the mini-mental state examination (mmse) less than 24 points. * present hemoglobin levels below 10g / dl. withdrawal criteria: * exitus of the patient. * progression of the disease leading to a terminal state. * hospitalization of the patient at the time of home monitoring. * do not carry out final assessment.

Keywords: cancer rehabilitation occupational therapy fatigue
eye movement recordings in the diagnosis of traumatic brain injury

Conditions: Traumatic Brain Injury

Summary: the study investigates whether the use of eye movement recordings can provide a reliable diagnostic of previously undiagnosed mild traumatic brain injury (blast and impact) in operations enduring freedom or iraqi freedom (oif/oef) veterans.

eye movements are recorded for operations enduring freedom or iraqi freedom (oif/oef) veterans with mild traumatic brain injury (mtbi) and compared to the eye movements of those without mtbi. by analyzing and characterizing the differences between the two groups, a diagnostic measure of mtbi through the use of eye movements can be developed.

Eligibility criteria:
inclusion criteria: * oif/oef veteran; * neuropsych diagnosis of mtbi exclusion criteria: * chronically abusing alcohol or illicit drugs. * uncorrected vision prevents subject from effectively viewing the stimuli, unless they can wear contact lenses during the recording session. * inability to make normal eye movements (i.e.: saccades, smooth pursuit) required by study paradigms. note: deficit can be caused by taking medications that can potentially affect eye movements or any neurological condition that can interfere with making normal eye movement. * psychological or psychiatric conditions that preclude sustained concentration or ability to perform the tasks.

Keywords: traumatic brain injury eye movement recording
a disease registry encompassing the care of patients with multiple myeloma on panobinostat

Conditions: Multiple Myeloma

Summary: this study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.


Eligibility criteria:
inclusion criteria: * willing and able to provide written informed consent * at least 18 years of age * clinical diagnosis of multiple myeloma that meets published diagnostic criteria * initiating panobinostat within 60 days of enrollment * ecog performance status 0-1 * availability of documentation from the patient's medical records regarding previous myeloma treatment, response, and duration of response * willing and able to complete the pro questionnaire exclusion criteria: * diagnosed with any b-cell malignancy other than myeloma * estimated life expectancy \<6 months * currently enrolled in any interventional clinical trial at study entry (note: patients who enroll in an interventional clinical trial after enrollment may remain in the registry)

Keywords: farydak panobinostat
effectiveness of the neuroadaptative for urge incontinence

Conditions: Urge Incontinence

Summary: in this clinical trials the sponsor want to assess a self-controlled-energo-neuroadaptative-regulation in patient with urge incontinence

in this clinical trials the sponsor want to assess a self-controlled-energo-neuroadaptative-regulation in patient with urge incontinence and mixted incontinence

Eligibility criteria:
inclusion criteria: * urge incontinence or mixed incontinence without urethral hypermobility * over 3 months of disease evolves. exclusion criteria: * severe physical limitations that might interfere with applying the treatment. * severe mental disorders that need pharmacology treatments that may influence in neuronal activity * oncological processes in the lower abdomen that had required radical surgery. * neurogenic bladder. * blockage of the bladder * vaginal infection * bladder infection or disorder of kidney function * have received, in the last year, botulinum toxin in bladder or pelvic organs. * have received pharmacological treatment for urge incontinence in the last month (before entry date in the trial) * be receiving pharmacological treatment for urge incontinence. * stress incontinence due to urethral hypermobility which was treatable with surgery. * pregnant women * patients with pacemarker